BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Strides Pharma Science Ltd. reported a lower than expected performance in Q2 FY22 due to continued headwinds in the U.S. business.
Sales in other regulated markets witnessed a recovery, with an 18% YoY growth.
With the completion of Endo products and facility acquisition, Strides Pharma will have a diversified U.S. portfolio, with a lower proportion of acute products as well as differentiated products such as hormones, nasal sprays, gels, modified release products, and controlled substances, which are less susceptible to price shocks like that seen in H1 FY22.
Other regulated/emerging markets are expected to continue their strong growth trajectory.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR